Stopped
LY3541860 · Relapsing Multiple Sclerosis
Trial terminated
Eli Lilly and CompanyPhase 2 NCT06220669 Registry history of NCT06220669 on ClinicalTrials.gov (opens the registry)
44 trials changed in the last 30 days: 1 stopped, 17 with notable changes, 26 with minor changes only.
Trial terminated
Eli Lilly and CompanyPhase 2 NCT06220669 Registry history of NCT06220669 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 16, 2026
Also in this update: Primary endpoint(s) modified; Trial completed
Eli Lilly and CompanyPhase 3 NCT06280716 Registry history of NCT06280716 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Interventions modified; Trial arms changed: 3 → 4
Eli Lilly and CompanyPhase 1 NCT06465069 Registry history of NCT06465069 on ClinicalTrials.gov (opens the registry)
Phase changed: Phase 1/2 → Phase 3
Also in this update: Primary endpoint(s) modified; Sponsor changed: Akouos, Inc. to Eli Lilly and Company
Eli Lilly and CompanyPhase 3 NCT05821959 Registry history of NCT05821959 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jan 2028 to Oct 2028
Also in this update: Enrollment reduced: 127 → 90 participants
Eli Lilly and CompanyPhase 1 NCT06809400 Registry history of NCT06809400 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 2027 to Sep 2028
Eli Lilly and CompanyPhase 1 NCT07226843 Registry history of NCT07226843 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Sep 2026 to Jul 8, 2026
Eli Lilly and CompanyPhase 3 NCT07668336 Registry history of NCT07668336 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Start date changed from estimate of Sep 2026 to Oct 14, 2025
Eli Lilly and CompanyPhase 1 NCT07787182 Registry history of NCT07787182 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 3 NCT07817875 Registry history of NCT07817875 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 3 NCT07775300 Registry history of NCT07775300 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 2 NCT07759245 Registry history of NCT07759245 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07801300 Registry history of NCT07801300 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07808060 Registry history of NCT07808060 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07808073 Registry history of NCT07808073 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07787169 Registry history of NCT07787169 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07803744 Registry history of NCT07803744 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyPhase 1 NCT07818967 Registry history of NCT07818967 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Eli Lilly and CompanyNot specified NCT07254234 Registry history of NCT07254234 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion moved earlier from Mar 2029 to Mar 2028
Eli Lilly and CompanyPhase 1 NCT06586515 Registry history of NCT06586515 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 2026 to Sep 9, 2026
Eli Lilly and CompanyPhase 2 NCT02747004 Registry history of NCT02747004 on ClinicalTrials.gov (opens the registry)
Trial completed
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Phase 2 NCT05611671 Registry history of NCT05611671 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 4 NCT07006792 Registry history of NCT07006792 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 1 NCT07662798 Registry history of NCT07662798 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary completion date changed from estimate of Dec 2026 to Apr 2, 2025
Eli Lilly and CompanyPhase 1 NCT05307705 Registry history of NCT05307705 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 3 NCT07153471 Registry history of NCT07153471 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 2 NCT07215559 Registry history of NCT07215559 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
And 2 more changes in the last 30 days
Eli Lilly and CompanyPhase 2 NCT06598943 Registry history of NCT06598943 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 2 NCT06603571 Registry history of NCT06603571 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 1 NCT07707375 Registry history of NCT07707375 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 1 NCT06280703 Registry history of NCT06280703 on ClinicalTrials.gov (opens the registry)
Trial completed
Eli Lilly and CompanyPhase 1 NCT07545590 Registry history of NCT07545590 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Eli Lilly and CompanyPhase 1 NCT07701083 Registry history of NCT07701083 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 2030 to Sep 2030
Also in this update: Trial sites expanded: 9 → 12 locations; Start date pushed from Oct 2026 to Nov 2026
Eli Lilly and CompanyPhase 4 NCT07838155 Registry history of NCT07838155 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 2026 to Nov 2026
Eli Lilly and CompanyPhase 1 NCT06606106 Registry history of NCT06606106 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Aug 2026 to Nov 2026
Eli Lilly and CompanyPhase 1 NCT07165002 Registry history of NCT07165002 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 2026 to Mar 2027
Eli Lilly and CompanyPhase 1 NCT06945406 Registry history of NCT06945406 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 0 → 18 locations
Eli Lilly and CompanyPhase 2 NCT07814417 Registry history of NCT07814417 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 136 → 131 locations
Eli Lilly and CompanyPhase 3 NCT07222332 Registry history of NCT07222332 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 148 → 143 locations
Eli Lilly and CompanyPhase 3 NCT07282600 Registry history of NCT07282600 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 284 → 276 locations
Eli Lilly and CompanyPhase 3 NCT07218380 Registry history of NCT07218380 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 10 locations
And 1 more change in the last 30 days
Eli Lilly and CompanyPhase 4 NCT07822880 Registry history of NCT07822880 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 15 locations
Eli Lilly and CompanyPhase 1 NCT07598370 Registry history of NCT07598370 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 2026 to Dec 2027
Eli Lilly and CompanyPhase 2 NCT05440786 Registry history of NCT05440786 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from May 2029 to Feb 2029
Also in this update: Primary completion moved earlier from May 2028 to Feb 2028
Eli Lilly and CompanyPhase 1/2 NCT06721013 Registry history of NCT06721013 on ClinicalTrials.gov (opens the registry)
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-22 | NCT07890376 A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With… | Phase 2 | Not Yet Recruiting |
| 2026-10-20 | NCT07881887 A Study of LY4167586 in Participants With Obesity or Overweight With or Without Type 2… | Phase 1 | Not Yet Recruiting |
| 2026-10-20 | NCT07883590 A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral… | Phase 1 | Not Yet Recruiting |
| 2026-10-19 | NCT07881432 A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Phase 3 | Not Yet Recruiting |
| 2026-10-19 | NCT07881458 A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Not Yet Recruiting |
| 2026-10-09 | NCT07867327 A Study of LY4515100 in Healthy Male Participants | Phase 1 | Not Yet Recruiting |
| 2026-10-09 | NCT07867340 A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including… | Phase 1 | Not Yet Recruiting |
| 2026-09-28 | NCT07843459 A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease… | Phase 1 | Not Yet Recruiting |
| 2026-09-24 | NCT07838155 A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's… | Phase 4 | Not Yet Recruiting |
| Phase 1 | 71 | |
| Phase 1/2 | 5 | |
| Phase 2 | 43 | |
| Phase 2/3 | 1 | |
| Phase 3 | 93 | |
| Phase 4 | 11 |
Obesity (54) · Diabetes (27) · Breast Cancer (24) · Type 2 Diabetes (20) · Alzheimer's Disease (19) · Dementia (19) · Lung Cancer (19) · Non-Small Cell Lung Cancer (NSCLC) (19) · Colorectal Cancer (10) · Head & Neck Cancer (8)